Efforts to develop off-the-shelf (OTS) cell therapies are accelerating across global biotech, as researchers aim to make next ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the ...

A novel in vivo CD19 CAR-T therapy achieved complete remission in a DLBCL patient without lymphodepletion, showing sustained efficacy over three months. The therapy demonstrated safety, with no ...